Dev48
Language
  • About
  • Services
  • Industries
  • Technologies
  • Articles
  • Contacts
Book a call
    Home/Articles/Boston scientific announces participation in wells fargo 21st annual healthcare
Dev48

© 2026 · All rights reserved.

Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results

Источник: Boston Scientific

Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results

Source: Boston Scientific

Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 21st Annual Healthcare Conference on Thursday, September 10, 2026. Mike Mahoney, chairman and chief executive officer,...

September 29, 2026•Updated: September 29, 2026

Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results

, /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 21 Annual Healthcare Conference on Thursday, September 10, 2026. Mike Mahoney, chairman and chief executive officer, and Kenneth Stein, M.D., senior vice president and global chief medical officer, will participate in a 35-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET.

Additionally, the company will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2026, on Wednesday, October 28, 2026, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter 2026 on October 28 prior to the conference call.

A live webcast and replay for each event will be accessible at https://investors.bostonscientific.com. The replays will be available approximately one hour following the completion of each event.

About Boston ScientificBoston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.

CONTACTS: Chanel Hastings Media Relations +1 (508) 382-0288Chanel.Hastings@bsci.com

Lauren TenglerInvestor Relations+1 (508) 683-4479BSXInvestorRelations@bsci.com

SOURCE Boston Scientific Corporation

← All articles

More in HealthTech & MedTech

All →
Sennheiser Momentum 5 review: Great sound, incredible battery life, and few compromisesПресса
Momentum

Sennheiser Momentum 5 review: Great sound, incredible battery life, and few compromises

Ready or not, VBC: 10 questions to consider
Athenahealth

Ready or not, VBC: 10 questions to consider

How independent practices succeed in value-based care
Athenahealth

How independent practices succeed in value-based care

Are you ready for a value-based care model?
Athenahealth

Are you ready for a value-based care model?

Last 24 hours to save up to $200 on TechCrunch Disrupt 2026. Reason 5 of 5 to attend: MomentumПресса
Momentum

Last 24 hours to save up to $200 on TechCrunch Disrupt 2026. Reason 5 of 5 to attend: Momentum

Efficient processes, data-driven growth, and happy providers
Athenahealth

Efficient processes, data-driven growth, and happy providers

More from Boston Scientific

Boston Scientific announces results for second quarter 2026
Boston Scientific

Boston Scientific announces results for second quarter 2026

FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Boston Scientific

FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints

Boston Scientific enters into $2 billion accelerated share repurchase agreement
Boston Scientific

Boston Scientific enters into $2 billion accelerated share repurchase agreement

Boston Scientific announces strategic investment in MiRus LLC
Boston Scientific

Boston Scientific announces strategic investment in MiRus LLC